{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T21:25:32Z","timestamp":1773782732814,"version":"3.50.1"},"reference-count":27,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes & Metabolic Syndrome: Clinical Research & Reviews"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.dsx.2020.08.039","type":"journal-article","created":{"date-parts":[[2020,9,6]],"date-time":"2020-09-06T18:22:57Z","timestamp":1599416577000},"page":"1759-1768","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Efficacy and safety of saroglitazar in managing hypertriglyceridemia in type-2 diabetes: A meta-analysis"],"prefix":"10.1016","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4915-8805","authenticated-orcid":false,"given":"Deep","family":"Dutta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saptarshi","family":"Bhattacharya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vineet","family":"Surana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sameer","family":"Aggarwal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajiv","family":"Singla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepak","family":"Khandelwal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meha","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.dsx.2020.08.039_bib2","doi-asserted-by":"crossref","first-page":"401","DOI":"10.4103\/0971-5916.184281","article-title":"Intervening at prediabetes stage is critical to controlling the diabetes epidemic among Asian Indians","volume":"143","author":"Dutta","year":"2016","journal-title":"Indian J Med Res"},{"issue":"4","key":"10.1016\/j.dsx.2020.08.039_bib3","doi-asserted-by":"crossref","first-page":"441","DOI":"10.4103\/ijmr.IJMR_1938_18","article-title":"Young-onset diabetes: an Indian perspective","volume":"149","author":"Dutta","year":"2019","journal-title":"Indian J Med Res"},{"key":"10.1016\/j.dsx.2020.08.039_bib4","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0096808","article-title":"Prevalence of dyslipidemia in urban and rural India: the ICMR-INDIAB study","volume":"9","author":"Joshi","year":"2014","journal-title":"PloS One"},{"key":"10.1016\/j.dsx.2020.08.039_bib5","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s12933-019-0884-3","article-title":"New dual peroxisome proliferator activated receptor agonist-Saroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: integrated analysis of the real world evidence","volume":"18","author":"Kaul","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.dsx.2020.08.039_bib6","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.dsx.2020.08.039_bib7","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and metaanalyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"issue":"7650","key":"10.1016\/j.dsx.2020.08.039_bib8","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ (Clinical research ed)"},{"key":"10.1016\/j.dsx.2020.08.039_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta4100","article-title":"Publication and related biases","volume":"4","author":"Song","year":"2000","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.dsx.2020.08.039_bib10","first-page":"4","article-title":"Comparison of effectiveness and safety of add-on therapy of saroglitazar and fenofibrate with metformin in Indian patients with diabetic dyslipidaemia","volume":"10","author":"Ghosh","year":"2016","journal-title":"J\u00a0Clin Diagn Res"},{"key":"10.1016\/j.dsx.2020.08.039_bib11","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-55466-3","article-title":"Effect of a dual PPAR \u03b1\/\u03b3 agonist on insulin sensitivity in patients of type 2 diabetes with hypertriglyceridemia- randomized double-blind placebo-controlled trial","volume":"9","author":"Jain","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.dsx.2020.08.039_bib12","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1089\/dia.2013.0253","volume":"16","author":"Jani","year":"2014","journal-title":"Diabetes Technol Therapeut"},{"key":"10.1016\/j.dsx.2020.08.039_bib13","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1177\/1932296813518680","article-title":"A\u00a0multicenter, prospective, randomized, double-blind study to evaluate the safety and efficacy of saroglitazar 2 and 4 mg compared to pioglitazone 45 mg in diabetic dyslipidemia (PRESS V)","volume":"8","author":"Pai","year":"2014","journal-title":"J\u00a0Diabetes Sci Technol"},{"key":"10.1016\/j.dsx.2020.08.039_bib14","doi-asserted-by":"crossref","DOI":"10.1007\/s00592-020-01487-8","article-title":"Abrogation of postprandial triglyceridemia with dual PPAR \u03b1\/\u03b3 agonist in type 2 diabetes mellitus: a randomized, placebo-controlled study","author":"Rastogi","year":"2020","journal-title":"Acta Diabetol"},{"key":"10.1016\/j.dsx.2020.08.039_bib15","first-page":"14","article-title":"Study of saroglitazar in treatment of pre-diabetes with dyslipidemia: stop-d","volume":"66","author":"Deepak","year":"2018","journal-title":"J\u00a0Assoc Phys India"},{"key":"10.1016\/j.dsx.2020.08.039_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0146222","article-title":"A\u00a0prospective, multicentre, open-label single-arm exploratory study to evaluate efficacy and safety of saroglitazar on hypertriglyceridemia in HIV associated lipodystrophy","volume":"11","author":"Deshpande","year":"2016","journal-title":"PloS One"},{"key":"10.1016\/j.dsx.2020.08.039_bib17","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s13300-016-0167-x","article-title":"Diabetes dyslipidemia","volume":"7","author":"Schofield","year":"2016","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.dsx.2020.08.039_bib18","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1016\/S0140-6736(10)60545-4","article-title":"Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies","volume":"375","author":"Sarwar","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.dsx.2020.08.039_bib19","doi-asserted-by":"crossref","first-page":"7b","DOI":"10.1016\/S0002-9149(98)00031-9","article-title":"Hypertriglyceridemia as a cardiovascular risk factor","volume":"81","author":"Austin","year":"1998","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.dsx.2020.08.039_bib20","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1161\/CIRCULATIONAHA.113.002529","article-title":"Association between plasma triglycerides and high-density lipoprotein cholesterol and microvascular kidney disease and retinopathy in type 2 diabetes mellitus: a global case-control study in 13 countries","volume":"129","author":"Sacks","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.dsx.2020.08.039_bib21","doi-asserted-by":"crossref","first-page":"811","DOI":"10.2337\/dc08-9018","article-title":"Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American diabetes association and the American college of cardiology foundation","volume":"31","author":"Brunzell","year":"2008","journal-title":"Diabetes Care"},{"key":"10.1016\/j.dsx.2020.08.039_bib22","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.numecd.2017.03.001","article-title":"Statin use and risk of new-onset diabetes: a meta-analysis of observational studies","volume":"27","author":"Casula","year":"2017","journal-title":"Nutr Metabol Cardiovasc Dis"},{"key":"10.1016\/j.dsx.2020.08.039_bib23","doi-asserted-by":"crossref","first-page":"5020","DOI":"10.1021\/jm9804127","article-title":"N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents","volume":"41","author":"Henke","year":"1998","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.dsx.2020.08.039_bib24","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1080\/13547500500218682","article-title":"Biomarkers for early effects of carcinogenic dual-acting PPAR agonists in rat urinary bladder urothelium in\u00a0vivo","volume":"10","author":"Egerod","year":"2005","journal-title":"Biomarkers"},{"key":"10.1016\/j.dsx.2020.08.039_bib25","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.2337\/dc05-1146","volume":"29","author":"Kendall","year":"2006","journal-title":"Diabetes Care"},{"key":"10.1016\/j.dsx.2020.08.039_bib26","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.2337\/dc11-1811","article-title":"Reversibility of fenofibrate therapy-induced renal function impairment in ACCORD type 2 diabetic participants","volume":"35","author":"Mychaleckyj","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.dsx.2020.08.039_bib27","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1159\/000064083","article-title":"Fenofibrate increases creatininemia by increasing metabolic production of creatinine","volume":"92","author":"Hottelart","year":"2002","journal-title":"Nephron"},{"key":"10.1016\/j.dsx.2020.08.039_bib28","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1053\/j.ajkd.2008.01.014","article-title":"Effect of fenofibrate on kidney function: a 6-week randomized crossover trial in healthy people","volume":"51","author":"Ansquer","year":"2008","journal-title":"Am J Kidney Dis"}],"container-title":["Diabetes & Metabolic Syndrome: Clinical Research & Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871402120303441?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871402120303441?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T09:20:56Z","timestamp":1761729656000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1871402120303441"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S1871402120303441"],"URL":"https:\/\/doi.org\/10.1016\/j.dsx.2020.08.039","relation":{},"ISSN":["1871-4021"],"issn-type":[{"value":"1871-4021","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of saroglitazar in managing hypertriglyceridemia in type-2 diabetes: A meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Diabetes & Metabolic Syndrome: Clinical Research & Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dsx.2020.08.039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Diabetes India. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}